ALX Oncology Holdings Inc (ALXO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.15-15.44%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · ALXO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 32.9% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
ALXO — dividend update
Dated 2026-10-15
Entry into a Material Definitive Agreement. On October 14, 2026, ALX Oncology Holdings Inc. (the “Company”) entered into separate privately-negotiated exchange agreements (each, an “Exchange Agreement”), with certain stockholders of the Company (collectively, the “Stockholders”), pursuant to which the Stockholders agreed to surrender an aggregate of 13,353,384 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), to the Company, and the Company agreed to issue…
Why it matters: The Phase 1 safety update is the next near-term test of this drug program. A delay or serious safety concern would weaken the case for continued progress.
Watch forALX reports early Phase 1 safety data by December 31, 2026. Dose increases continue, with no safety pause.
Also watch forALX reports a trial pause due to safety, or gives no safety update by December 31, 2026.
Why it matters: Stockholders agreed to give up 13.35 million common shares under exchange agreements. The next filing can show how the exchange changed the number of shares outstanding.
Watch forA company filing confirms that 13,353,384 shares were given up and reports the new common share count.
Also watch forA company filing says the exchange did not close or reports that fewer than 13,353,384 shares were surrendered.
Why it matters: Earlier results showed stronger responses in patients with high CD47 levels. The Phase 2 update can test whether this marker helps identify patients who respond.
Supportive ifA trial update shows stronger response results in patients with high CD47 levels than in patients with low levels.
Worry ifA trial update shows similar or lower response results in the high-CD47 group than in the low-CD47 group.
Why it matters: The Phase 2 trial aims to report data from 80 patients in mid-2027. A delay could push back a key test of evorpacept in breast cancer.
Worry ifAt the next company update, ALX says enrollment remains on track for data from 80 patients in mid-2027.
Less concerning ifALX says enrollment has slowed or the 80-patient data readout has moved beyond mid-2027.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$292 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $901 loss on $10,000 · 9.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,559 loss on $10,000 · 65.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: ALX reported $153.4 million in cash and said it could fund planned work through the first half of 2028. Cash updates can show whether trial plans remain funded.
Worry ifA company update keeps the stated funding window at least through the first half of 2028.
Less concerning ifA company update moves the funding window to before the first half of 2028, or says new funding is needed sooner.